<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00109655</url>
  </required_header>
  <id_info>
    <org_study_id>V-0046</org_study_id>
    <nct_id>NCT00109655</nct_id>
  </id_info>
  <brief_title>Dose-Escalation Study of CG0070 for Bladder Cancer After BCG (Bacillus Calmette-Guerin) Failure</brief_title>
  <official_title>A Phase 1 Dose-Escalation Trial of Intravesical CG0070 for Superficial Transitional Cell Carcinoma of the Bladder After Bacillus Calmette-Guerin Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cell Genesys</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cell Genesys</source>
  <brief_summary>
    <textblock>
      The main purpose of this research study is to evaluate the safety and dosing of CG0070.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cohorts of three to six patients will be assigned to receive intravesical (into the bladder)
      administration of CG0070 either Weekly or Every 4 Weeks for up to a total of 6 doses.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>April 2005</start_date>
  <completion_date type="Anticipated">September 2010</completion_date>
  <primary_completion_date type="Anticipated">October 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum-tolerated or maximum feasible dose in single and multidose regimens of CG0070 by intravesical administration</measure>
    <time_frame>Study End</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of the amount of CG0070 in the urine and blood over time by PCR</measure>
    <time_frame>Study End</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Carcinoma, Transitional Cell</condition>
  <condition>Bladder Neoplasms</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Oncolytic adenovirus (serotype 5) - CG0070</intervention_name>
    <description>Intravesical administration of CG0070 (in suspension) directly into the bladder</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  High grade non-muscle invasive bladder cancer (stages Ta, T1 and/or CIS - carcinoma in
             situ). High grade being defined as G2 or G3 disease.

          -  Failure of at least one prior treatment with BCG, defined as evidence of TCC on
             cystoscopic exam and biopsy or cystoscopic exam and urine cytology at least 6 weeks
             from last BCG treatment

          -  ECOG performance status 0-1

          -  Adequate bone marrow, renal, liver and coagulation function

        Exclusion Criteria:

          -  Pregnant or nursing

          -  HIV positive

          -  Use of anticoagulants such as coumadin or heparin

          -  History of bleeding disorder

          -  Active systemic autoimmune disease or chronic immunodeficiency

          -  Prior gene therapy

          -  Uncontrolled cystitis, bladder pain, bladder spasms, urinary incontinence, or reduced
             bladder volume
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>BCG Oncology</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCSF Comprehensive Cancer Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Billings Clinic</name>
      <address>
        <city>Billings</city>
        <state>Montana</state>
        <zip>59107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York Oncology Hematology</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Centers of the Carolinas</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mary Crowley Medical Research Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Male/Female Health and Research Centre</name>
      <address>
        <city>Barrie</city>
        <state>Ontario</state>
        <zip>L4M 7G1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Fe/Male Health Centre</name>
      <address>
        <city>Oakville</city>
        <state>Ontario</state>
        <zip>L6H 3P1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.cellgenesys.com</url>
  </link>
  <verification_date>October 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 2, 2005</study_first_submitted>
  <study_first_submitted_qc>May 2, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 3, 2005</study_first_posted>
  <last_update_submitted>October 1, 2008</last_update_submitted>
  <last_update_submitted_qc>October 1, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 3, 2008</last_update_posted>
  <responsible_party>
    <name_title>Cell Genesys, Inc</name_title>
    <organization>Cell Genesys, Inc</organization>
  </responsible_party>
  <keyword>Superficial Transitional Cell Carcinoma</keyword>
  <keyword>Bacillus Calmette-Guerin (BCG)</keyword>
  <keyword>Superficial Bladder Cancer</keyword>
  <keyword>Gene Therapy</keyword>
  <keyword>Vaccine</keyword>
  <keyword>Adenovirus</keyword>
  <keyword>Carcinoma in situ</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Transitional Cell</mesh_term>
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>BCG Vaccine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

